#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1890	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2349	236.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1790	1790	T	268	T	235	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	1890	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2349	236.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1524	1524	C	290	C	233	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3164	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3940	240.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1850	1850	A	275	A	236	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3164	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3940	240.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2484	2484	C	220	C,A	179,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3164	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3940	240.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2558	2558	A	235	A,C	196,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	3164	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3940	240.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	3110	3110	C	300	C	249	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	258	folP	855	855	100.0	folP.l15.c4.ctg.1	1958	39.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1175	1177	AGC	54;55;55	A,T;G;C,T	46,1;47;43,1	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	626	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3748	49.8	1	SNP	p	S91F	1	.	.	271	273	TTC	779	781	TTC	39;39;41	T;T,C;C	37;34,1;38	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	626	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3748	49.8	1	SNP	p	G95N	0	.	.	283	285	GGC	791	793	GGC	41;41;41	G;G;C	37;38;38	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	626	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3748	49.8	1	SNP	p	D95G	1	.	.	283	285	GGC	791	793	GGC	41;41;41	G;G;C	37;38;38	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	290	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1656	52.3	1	SNP	p	G45D	0	.	.	133	135	GGC	683	685	GGC	64;64;64	G;G;C	51;51;52	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	190	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1255	45.0	0	.	n	.	0	A197.	DEL	197	197	A	742	742	A	81	A	64	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	562	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3397	49.4	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1753	1755	GTC	75;75;75	G;T;C	63;62;63	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	562	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3397	49.4	1	SNP	p	D86N	0	.	.	256	258	GAC	859	861	GAC	48;48;49	G;A;C	42;40;41	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	562	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3397	49.4	1	SNP	p	R87I	0	.	.	259	261	CGT	862	864	CGT	49;50;50	C;G;T	42;44;42	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	562	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3397	49.4	1	SNP	p	R87W	0	.	.	259	261	CGT	862	864	CGT	49;50;50	C;G;T	42;44;42	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	562	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3397	49.4	1	SNP	p	S87R	1	.	.	259	261	CGT	862	864	CGT	49;50;50	C;G;T	42;44;42	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	562	parC	2304	2304	99.87	parC.l6.c17.ctg.1	3397	49.4	1	SNP	p	S88P	0	.	.	262	264	TCC	865	867	TCC	51;51;51	T;C;C	44;42;44	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	488	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3163	46.2	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1667	1669	TGC	61;61;61	T;G;C	51;50;51	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	488	parE	1986	1986	99.95	parE.l15.c4.ctg.1	3163	46.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1877	1879	GGC	62;62;61	G;G;C	51;50;46	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1414	1416	GCA	77;76;74	G;C;A	64;62;65	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1417	1419	ATC	75;75;76	A;T;C	63;61;62	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1429	1431	GTG	73;73;73	G;T,G;G	59;54,1;60	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1429	1431	GTG	73;73;73	G;T,G;G	59;54,1;60	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1933	1935	ACC	35;35;35	A;C;C	30;31;31	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1987	1989	GCG	39;39;38	G;C,G;G	31;29,1;29	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1987	1989	GCG	39;39;38	G;C,G;G	31;29,1;29	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2110	2112	GGC	54;54;54	G;G;C	45;45;44	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2119	2121	GGC	57;57;58	G;G;C,G	45;45;45,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	440	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2674	49.1	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2137	2139	TCG	61;62;63	T;C;G	48;50;50	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	678	ponA	2397	2397	100.0	ponA.l6.c4.ctg.1	3506	57.8	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1872	1874	CCG	67;67;66	C;C,T;G	51;53,1;50	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	290	porA	1146	1146	99.56	porA.l15.c4.ctg.1	2119	40.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	727	727	C	47	C	41	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	0	.	p	.	0	N38E	NONSYN	112	114	AAT	532	534	GAA	93;93;94	G;A;A	73;78;78	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	0	.	p	.	0	N134D	NONSYN	400	402	AAT	820	822	GAT	103;102;102	G,C;A,C;T,G	83,1;84,1;80,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	0	.	p	.	0	P175S	NONSYN	523	525	CCA	943	945	TCA	93;93;93	T;C;A	78;77;79	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1072	1074	GTC	85;85;85	G;T;C,A	73;77;75,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1402	1404	GCA	90;91;89	G;C;A	83;84;79	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	1	SNP	p	G120K	1	.	.	358	360	AAG	778	780	AAG	112;113;112	A;A;G	90;93;90	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	1	SNP	p	D121N	0	.	.	361	363	GAC	781	783	GAC	112;112;112	G;A;C	91;90;91	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	460	porB1b	1047	1047	99.33	porB1b.l6.c4.ctg.1	1896	71.5	1	SNP	p	A121D	1	.	.	361	363	GAC	781	783	GAC	112;112;112	G;A;C	91;90;91	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1354	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5205	77.7	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2254	2256	AAT	80;81;81	A;A;T	67;69;65	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	198	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1399	42.4	1	SNP	p	V57M	1	.	.	169	171	ATG	748	750	ATG	75;75;75	A;T;G,A	63;65;66,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
